Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell...

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Multiple Myeloma (MM) is often preceded by plasma cell proliferative disorders (PCPD), such as monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), or plasmacytoma.
• Autologous stem cell transplantation (SCT) is a standard treatment for MM, but its impact on patients with prior PCPD is not well understood.

Purpose of the Study:

• To investigate whether patients with a preceding PCPD diagnosis have different outcomes after SCT compared to those with de novo MM.
• To specifically analyze the impact of MGUS, SMM, and plasmacytoma as preceding conditions on post-SCT survival and progression.

Main Methods:

• Retrospective analysis of 151 patients with preceding PCPD undergoing SCT, compared to 804 patients with de novo MM.
• Comparison of response rates, time to progression (TTP), and overall survival (OS) post-transplant.
• Multivariate analysis to identify prognostic factors for post-transplant relapse.

Main Results:

• Overall response rates were similar between groups.
• Patients with preceding MGUS demonstrated significantly longer TTP (27.5 vs. 17.2 months) and OS (80.2 vs. 48.3 months) post-SCT compared to de novo MM patients (P=0.01 and P=0.03, respectively).
• No significant differences in TTP or OS were observed for patients with preceding SMM or plasmacytoma compared to de novo MM.

Conclusions:

• Pre-existing MGUS prior to MM diagnosis is associated with a better outcome following high-dose therapy and SCT.
• MGUS preceding MM suggests a more indolent disease course and favorable biology, impacting post-transplant relapse risk.
• Patients with preceding SMM or plasmacytoma do not show improved outcomes post-SCT compared to de novo MM.